Extended Data Fig. 6: Rapid and sustained inactivation of common KRAS mutants.
From: Pan-KRAS inhibitor disables oncogenic signalling and tumour growth
a, HEK293 cells expressing the indicated KRAS variants were treated as shown and analyzed to determine the effect on KRAS activation. b–d, The indicated cell lines were treated over time to determine the effect on KRAS activation (b–d) and ERK signaling intermediates (d). The cells in b and c were treated in serum-free medium, whereas those in a and d were treated in complete medium. A representative of two independent repeats is shown in a–d.
